565 related articles for article (PubMed ID: 25697481)
21. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
22. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
23. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
[TBL] [Abstract][Full Text] [Related]
25. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
26. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
27. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
[TBL] [Abstract][Full Text] [Related]
28. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
[TBL] [Abstract][Full Text] [Related]
29. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
30. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
[TBL] [Abstract][Full Text] [Related]
31. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
32. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
33. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
34. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
35. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
38. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
40. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
